CAPZA2::MET Fusion and MET Amplification in EGFR-Mutated Advanced Non–Small Cell Lung Cancer With Marked Response to Capmatinib Monotherapy: A Case Report
CAPZA2::MET Fusion and MET Amplification in EGFR-Mutated Advanced Non–Small Cell Lung Cancer With Marked Response to Capmatinib Monotherapy: A Case Report. // JTO Clinical and Research Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2666364326001426?dgcid=rss_sd_all
CAPZA2::MET Fusion and MET Amplification in EGFR-Mutated Advanced Non–Small Cell Lung Cancer With Marked Response to Capmatinib Monotherapy: A Case Report. JTO Clinical and Research Reports. https://www.sciencedirect.com/science/article/pii/S2666364326001426?dgcid=rss_sd_all
“CAPZA2::MET Fusion and MET Amplification in EGFR-Mutated Advanced Non–Small Cell Lung Cancer With Marked Response to Capmatinib Monotherapy: A Case Report.” JTO Clinical and Research Reports.
@article{article99017,
title = {CAPZA2::MET Fusion and MET Amplification in EGFR-Mutated Advanced Non–Small Cell Lung Cancer With Marked Response to Capmatinib Monotherapy: A Case Report},
journal = {JTO Clinical and Research Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2666364326001426?dgcid=rss_sd_all}
}